Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:ENGN NASDAQ:GLUE NASDAQ:JMAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.98+0.3%$15.45$7.08▼$17.49$309.83M0.7790,162 shs32,762 shsENGNenGene$6.07+1.7%$4.17$2.65▼$11.00$309.44M-0.39101,628 shs103,849 shsGLUEMonte Rosa Therapeutics$6.58-5.1%$5.01$3.50▼$12.40$405.45M1.42767,706 shs2.98 million shsJMACMaxpro Capital Acquisition$6.83+8.9%$5.76$7.50▼$19.22$91.71M0.0174,040 shs36,424 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.53%+1.08%-4.60%+11.33%+24.42%ENGNenGene+4.55%+9.94%+62.23%+83.69%-10.76%GLUEMonte Rosa Therapeutics+44.07%+44.38%+51.31%+51.64%+13.98%JMACMaxpro Capital Acquisition0.00%+32.36%+20.46%+5.49%+4,922.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$14.98+0.3%$15.45$7.08▼$17.49$309.83M0.7790,162 shs32,762 shsENGNenGene$6.07+1.7%$4.17$2.65▼$11.00$309.44M-0.39101,628 shs103,849 shsGLUEMonte Rosa Therapeutics$6.58-5.1%$5.01$3.50▼$12.40$405.45M1.42767,706 shs2.98 million shsJMACMaxpro Capital Acquisition$6.83+8.9%$5.76$7.50▼$19.22$91.71M0.0174,040 shs36,424 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.53%+1.08%-4.60%+11.33%+24.42%ENGNenGene+4.55%+9.94%+62.23%+83.69%-10.76%GLUEMonte Rosa Therapeutics+44.07%+44.38%+51.31%+51.64%+13.98%JMACMaxpro Capital Acquisition0.00%+32.36%+20.46%+5.49%+4,922.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.50Reduce$12.00-19.89% DownsideENGNenGene 3.00Buy$21.00245.96% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33133.03% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest JMAC, AMRN, ENGN, and GLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $18.009/8/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$7.00 ➝ $12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$219.36M1.41N/AN/A$23.62 per share0.63ENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AGLUEMonte Rosa Therapeutics$75.62M5.37N/AN/A$3.63 per share1.81JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)ENGNenGene-$55.14M-$1.90N/AN/AN/AN/A-39.86%-34.15%N/AGLUEMonte Rosa Therapeutics-$72.70M$0.3618.24N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)JMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest JMAC, AMRN, ENGN, and GLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q3 2025ENGNenGene-$0.5084-$0.57-$0.0616-$0.57N/AN/A8/7/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AENGNenGene$1.5826.05%N/AN/A N/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34ENGNenGene0.0910.3410.34GLUEMonte Rosa TherapeuticsN/A7.167.16JMACMaxpro Capital AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%ENGNenGene64.16%GLUEMonte Rosa Therapeutics79.96%JMACMaxpro Capital Acquisition73.18%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%ENGNenGene10.40%GLUEMonte Rosa Therapeutics6.50%JMACMaxpro Capital Acquisition19.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.28 millionOptionableENGNenGene3151.11 million45.79 millionN/AGLUEMonte Rosa Therapeutics9061.76 million57.75 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableJMAC, AMRN, ENGN, and GLUE HeadlinesRecent News About These CompaniesMaxpro Capital Acquisition (NASDAQ:JMAC) Stock Price Down 0.1% - Time to Sell?August 28, 2025 | marketbeat.comDenali Capital Acquisition Corp Ordinary Shares - Class AMay 23, 2024 | morningstar.comMDenali Capital Acquisition Corp Ordinary Shares - Class A DECA Stock QuoteJuly 21, 2023 | morningstar.comMApollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on NasdaqJune 6, 2023 | finance.yahoo.comMaxpro Capital Acquisition CorpApril 5, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJMAC, AMRN, ENGN, and GLUE Company DescriptionsAmarin NASDAQ:AMRN$14.98 +0.05 (+0.33%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.enGene NASDAQ:ENGN$6.07 +0.10 (+1.68%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Monte Rosa Therapeutics NASDAQ:GLUE$6.58 -0.35 (-5.05%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Maxpro Capital Acquisition NASDAQ:JMAC$6.83 +0.56 (+8.93%) As of 09/12/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
